Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

What It Covers

Frank LeDoux, McKinsey Asia veteran and new Aulus Capital venture partner, argues biopharma should embrace a multipolar world where US, China, Europe, and emerging regions collaborate rather than compete. The episode also covers Stargardt disease treatment advances, FDA Commissioner McCary's controversial public statements, and the plausible mechanism framework for rare diseases.

Key Questions Answered

• •Multipolar Biopharma Strategy: Rather than treating China's biopharma rise as a zero-sum threat, Western companies should selectively integrate regional strengths. LeDoux notes multinationals publicly decry China's growth while simultaneously investing billions there — a contradiction that reveals the real market logic: more therapies developed anywhere benefits patients everywhere, including US markets.
• •Europe as Cautionary Tale: Europe holds comparable population to the US and strong science infrastructure but lacks growth capital and competitive drug pricing. LeDoux argues that European pricing reform could directly unlock investment capital, and that the US risks replicating Europe's stagnation if current policy trends — described by former FDA Commissioner Gottlieb as "stepping on the brakes" — continue.
• •Stargardt Disease Pipeline Milestone: Beelite Bio's oral small molecule targeting visual cycle substrate reduction reached phase three endpoints in late 2024, positioning it for the first-ever Stargardt approval within the year. The drug slows toxic byproduct accumulation caused by dysfunctional ABCA4 protein, making it most effective for early-stage patients who retain more photoreceptor function.
• •Split AAV Technology Unlocks Large Gene Delivery: ABCA4, at 6.8 kilobases, exceeds the standard 5kb single-AAV capacity. Companies now use split intein AAV strategies — dividing the gene across two vectors that reconstitute into full-length protein inside the cell — enabling gene therapy for Stargardt. The RORA gene therapy in phase two showed a 54% reduction in atrophic lesion growth at 12 months.
• •FDA Plausible Mechanism Framework: FDA released draft guidance establishing a plausible mechanism framework — not pathway — primarily targeting bespoke therapies for ultra-rare conditions. The docket is open for comment from companies, academics, and patient advocates. Stakeholders including Tracy Beth Hoag expect the framework to expand beyond strict N-of-one applications while maintaining evidence guardrails for broader rare disease development.